Skip to content

Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France.

Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France. The French Fuchs' Follow-up Study, F3S

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03974230
Acronym
F3S
Enrollment
208
Registered
2019-06-04
Start date
2019-08-01
Completion date
2021-12-14
Last updated
2023-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fuchs Endothelial Corneal Dystrophy

Keywords

Cornea, Fuchs Endothelial Corneal Dystrophy (FECD), slit lamp, Transcription Factor 4 (TCF4), chromosome 18, genetic

Brief summary

The pathophysiology of the most common corneal endothelial dystrophies (Fuchs' Corneal Endothelial Dystrophy (FECD)) is beginning to be dismembered. One of the most common genetic anomalies is a triplet repetition in one of the introns of the Transcription Factor 4 (TCF4) gene located on chromosome 18. However, the number of repetitions varies greatly from one patient to another.

Detailed description

The intent of that study was to analyse if there is a relationship between the number of triplet repetitions and the rate of disease progression. This knowledge would make it possible to personalize the care.

Interventions

Collection of datas of examination for diagnosis and follow-up of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.

BIOLOGICALblood sample

Blood sample will be performed (genetic analyses).

Slit lamp examination will be performed.

Sponsors

Kyoto University, Graduate School of Medicine
CollaboratorOTHER
Centre Hospitalier Universitaire de Saint Etienne
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

For patient group: * \>18 years old * affiliated with or entitled to a social security scheme * having received informed information about the study and having co-signed, with the investigator, a consent to participate in the study * with an Fuchs Endothelial Corneal Dystrophy (FECD) certified by slit lamp examination For control group: * \>18 years old * affiliated with or entitled to a social security scheme * having received informed information about the study and having co-signed, with the investigator, a consent to participate in the study

Exclusion criteria

For patient group: * Patients under guardianship or curatorship * Patient planning to move within the year * With no evidence of ophthalmological pathology requiring intraocular surgery within one year of the first visit * Better initial corrected visual acuity \<1/10 * Not having had intraocular surgery in the 6 months prior to inclusion (after 6 months, the endothelium is considered stabilized) * Not having any other progressive pathology responsible for a decrease in visual acuity (significant cataract Lens Opacities Classification System (LOCS) \>2 ; progressive retinal pathology, in particular age-related macular degeneration, unstabilized macular edema) For control group: * Patients under guardianship or curatorship * with an Fuchs Endothelial Corneal Dystrophy (FECD) certified by slit lamp examination

Design outcomes

Primary

MeasureTime frameDescription
Visual acuityYear: 0 and 1Correlation between visual acuity measured before noon eye by eye of ETDRS scale (international standardized Early Treatment Diabetic Retinopathy Study scale) results and number of CTG triplet repetitions in the intron of the Transcription Factor 4 (TCF4) gene.

Secondary

MeasureTime frameDescription
Mutation rs613872Year: 0 and 1Analysis frequency of the mutation rs613872 in the intron of the Transcription Factor 4 (TCF4) gene.
Other mutationYear: 0 and 1Analysis frequency of the other mutation type nucleotide polymorphisms in the intron of the Transcription Factor 4 (TCF4) gene.
Refraction with the auto-refractor tonometryYear: 0 and 1Analysis refraction with the auto-refractor tonometry non-contact air.
CTG triplet repetitions in the intron of the Transcription Factor 4 (TCF4) geneYear: 0 and 1Analysis number of CTG triplet repetitions in the intron of the Transcription Factor 4 (TCF4) gene.
interferometry, tear meniscus height, Non Invasive Break-Up Time (NIBUT) and meibographyYear: 0 and 1Correlation between interferometry, tear meniscus height, Non Invasive Break-Up Time (NIBUT) and meibography results.
Corneal thickness in Optical Coherence Tomography (OCT)Year: 0 and 1Comparison corneal thickness in Optical Coherence Tomography (OCT).
Reflectivity results measure by Optical Coherence Tomography (OCT)Year: 0 and 1Comparison reflectivity results measure by Optical Coherence Tomography (OCT). Optical Coherence Tomography (OCT) is an imaging technique, which is able to produce, in vivo, cross-sectional images of lesions.
ETDRS scale (Early Treatment Diabetic Retinopathy Study scale) in a controlled glare situationYear: 0 and 1Correlation between visual acuity measured before noon eye by eye on the ETDRS scale (Early Treatment Diabetic Retinopathy Study scale) in a controlled glare situation. ETDRS (Early Treatment Diabetic Retinopathy Study) scale will be allowed to measure visual acuity uses an eye chart with 5 letters per line. The scores range from 0 (no letters read correctly) to 100 (all letters read correctly).

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026